Most readers may have noticed that I riffed off of the Reuters October 30 “exclusive,” pointing out why it might not happen very quickly, or at all.
Now Reuters’ “news analysis” desk, albeit 48 hours later, agrees with me. Sweet. The Reuters desk quite helpfully — and rightly — points out that there are competitive drug/feed supplements busily making inroads, with each passing day that Merck’s product remains off the market, as well. That’s significant, because at least one of the competitive products is specifically acceptable in the Japanese, and Asian (more generally) beef supply chains.